TABLE 1.
Effects of potential pharmacological inhibitors on the release of ISF
| Exptl protocola | nb | ΔIsc (μA · cm−2) (mean ± SEM) | Inhibition (%) | Pc | Pharmacology |
|---|---|---|---|---|---|
| SUP. MφS + RPMI medium | 9 | 20 ± 3.1 | <0.01 | RPMI medium | |
| SUP. MφS + TxA (1 μM) | 8 | 91 ± 15.2 | TxA from C. difficile | ||
| SUP. MφS + TxA + dexamethasone (10 μM) | 7 | 36 ± 7.1 | 60 | <0.01 | Phospholipase A2 and cytokine synthesis inhibitor |
| SUP. MφS + TxA + quinacrine (10 μM) | 6 | 42 ± 6.1 | 54 | <0.05 | Phospholipase A2 inhibitor |
| SUP. MφS + TxA + indomethacin (10 μM) | 6 | 35 ± 6.1 | 62 | <0.01 | Cyclo-oxygenase inhibitor |
| SUP. MφS + TxA + MK 886 (10 μM) | 8 | 81 ± 18.1 | NS | NS | Lipo-oxygenase inhibitor |
| SUP. MφS + TxA + NDGA (1 μM) | 5 | 47 ± 3.6 | 48 | <0.05 | Dual cyclo- and lipo-oxygenase inhibitor |
| SUP. MφS + TxA + BN 52021 (10 μM) | 6 | 41 ± 9.7 | 55 | <0.05 | PAF antagonist |
| SUP. MφS + TxA + pentoxifylline (500 μM) | 6 | 47 ± 7.2 | 48 | <0.05 | TNF-α synthesis inhibitor |
| SUP. MφS + TxA + thalidomide (15 μM) | 6 | 48 ± 11.2 | 47 | <0.05 | TNF-α synthesis inhibitor |
a
Each experiment was repeated at least four times. SUP. MφS, supernatants from macrophages.
b
Total number of Üssing chambers containing rabbit ileum.
c
Statistical significance of the SUP. MφS+TxA group compared to the other experimental groups. NS, not significant (P > 0.05).